🔗 Share this article

As the United States undertakes unprecedented changes to its vaccination recommendations, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus vaccinations during the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Schedule

Agency leaders were set to unveil radical changes to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s immunization schedule, according to reports – a major change that would put the US out of alignment with many the international standard with little proof for improved outcomes. This reveal has been postponed until the next year.

Rather than the top vaccines chief, Dr. Høeg is set to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to run the division this year.

A New Direction at the Regulatory Body

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending some childhood shot schedules in the US in order to be more similar to Denmark, a society with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – typically the domain of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Expertise

The appointee has no obvious background in pharmaceutical research, oversight or leadership, which has been standard for past leaders of the CBER. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who led the center have had.”

CDER has an vast range of responsibilities at the FDA, the former commissioner pointed out.

“The public just pays attention on the innovative therapies, but the generic drug division approves thousands of generic drugs. There is also a biosimilars program, OTC medication office and so forth, and each of these need to be supervised,” Dr. Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a major management element to the position, which oversees in excess of 5,000 employees. “It is a enormous management job, if you execute it properly,” the former official said.

Official Statement and Disputed Programs

When asked about questions about Dr. Høeg's fitness for the role and whether this assignment signifies more teamwork among agency officials on vaccines, a press secretary responded that the “inquiries are based on flawed premises”.

“Her experience is consistent with the functions of her role,” the representative stated, citing the period Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious one-day medication authorization process that reportedly concerned her preceding directors. “How are these drugs being selected for this voucher program? Who takes the decisions?” Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

In general, he said, “the agency appears to be shifting towards less stringent rules of most medications, except for vaccines.”

Documented History on Immunizations

With immunizations, Dr. Høeg has a more established, if concerning, track record, Howard observe. She released a study using unconfirmed crowd-sourced reports to assess the incidence of myocarditis after Covid immunization. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are riskier than they are.

Part of her “wish list” for the current government encompassed revising rules for new vaccines and ending “optional” vaccines, she stated following the vote on a audio program. At the agency, Dr. Høeg has according to sources suggested preventing teenage boys from receiving Covid vaccines.

“She is an all-around dogmatist who commences with her preconceived notions and reverse-engineers to accommodate the data in a extremely disingenuous, untruthful way,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined fellow skeptics, {like|